As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP).
A study led by researchers at St. Jude Children’s Research Hospital shows that microbial cell-free DNA sequencing can predict bloodstream infections in children with leukemia days before the infection is apparent.
